Chiasma, Inc. (CHMA)
(Delayed Data from NSDQ)
$6.07 USD
+0.14 (2.36%)
Updated May 3, 2019 04:00 PM ET
After-Market: $6.03 (%) 5:22 PM ET
NA Value NA Growth NA Momentum NA VGM
View All Zacks #1 Ranked Stocks
Brokerage Reports
0 items in cart
[CHMA]
Reports for Purchase
Showing records 1 - 20 ( 100 total )
Industry: Medical - Biomedical and Genetics
Chiasma Acquired by Amryt Pharma in All-Stock Deal; Price Target to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Price: 25.00
Industry: Medical - Biomedical and Genetics
The Present and Future of Endocrinolgy: Takeaways From ENDO
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Price: 25.00
Industry: Medical - Biomedical and Genetics
MPOWERED Data at ENDO2021 Shows Mycapssa?s Benefit Beyond Just IGF-1 Control; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Price: 25.00
Industry: Medical - Biomedical and Genetics
Fundamentals in Place Though Launch Ramp Impacted by Realities of COVID; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Price: 10.00
Industry: Medical - Biomedical and Genetics
Carcinoid Syndrome Seems Sensible Target and We Include in Our Model Ahead of 4Q20 Earnings; Reit Buy, PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Price: 10.00
Industry: Medical - Biomedical and Genetics
Price: 50.00
Industry: Medical - Biomedical and Genetics
Three Key Takeaways From KOL Call Support Broad Mycapssa Adoption Driven by Patients; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Price: 10.00
Industry: Medical - Biomedical and Genetics
Mycapssa Hits Primary Endpoint in MPOWERED With EU Submission Expected in Mid-2021; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Price: 10.00
Industry: Medical - Biomedical and Genetics
Mycapssa Launch Kicks off With Strong Engagement Campaign; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Price: 10.00
Industry: Medical - Biomedical and Genetics
Mycapssa Commercial Launch Takes off; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Price: 10.00
Industry: Medical - Biomedical and Genetics
We are updating coverage of our Healthcare sector to better allocate our research resources in
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Price: 10.00
Industry: Medical - Biomedical and Genetics
Mycapssa is Lining up for Launch in 4Q; Reiterate Buy, PT Nudged to $10 From $11
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Price: 10.00
Industry: Medical - Biomedical and Genetics
More of the Same: OPTIMAL OLE Further Validates Mycapssa; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Price: 10.00
Industry: Medical - Biomedical and Genetics
Mycapssa Earns FDA Approval; Price Target to $11.00
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Price: 25.00
Industry: Medical - Biomedical and Genetics
Price: 10.00
Industry: Medical - Biomedical and Genetics
Price: 150.00
Industry: Medical - Biomedical and Genetics
Price: 10.00
Industry: Medical - Biomedical and Genetics
Figuring Out Mycapssa''s Commercial Strategy, with Raj Kannan
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Price: 25.00
Industry: Medical - Biomedical and Genetics
1Q First Impressions: PDUFA on the Horizon With Mycapssa on Track for 4Q Launch; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Price: 10.00
Industry: Medical - Biomedical and Genetics
Price: 10.00